And 8 down-regulated proteins, in ascites of chemoresistant tumors compared with chemosensitive tumors were successfully identified. The peptide count of the identified proteins varied from 4 to 33. Fold changes of levels of the 11 identified proteins in the two groups along with the detailed Mascot search results are given in Table 2. Several proteins were identified in multiple spots. For example, spots 1421, 1593, and 1598 were each identified as the transthyretin protein, which is a transport and acute phase protein, or its variants. Similarly, spots 1614 and 1626 were identified as haptoglobin, while spots 1536 and 1543 wereELISA ValidationAscites samples 12926553 (5 mL) were centrifuged at 2,000 rpm for 15 min at 4uC to separate the fluid from cellular components. The Eliglustat suspension was briefly sonicated, and the debris was centrifuged at 14,000 rpm for 10 min at 4uC. The supernatant was resuspended and stored at 280uC. ELISA assay kits for each of the analytes selected for further analysis were purchased from Abcam. These analytes were as follows: apoliprotein A-IV (Apo-AIV), ceruloplasmin, transthyretin and haptoglobin. Assays were performed following the instructions of the kit. Briefly, the color change due to the enzyme-substrate reaction of each well in the microtiter plate was measured spectrophotometrically at a wavelength of 450 nm. The concentration of each tested protein in the sample was then determined 
by comparing the optical density (OD) to that of the standard curve. Student’s t-test was conducted to compare differences between serum protein values. The SPSS 16.0 software package (SPSS, Chicago, IL, USA) was used to conduct the statistical analyses, and a two-tailed P value of less than 0.05 was considered statistically significant.Biomarkers for Chemoresistant Ovarian CancerTable 1. Clinical characteristics of study subjects.No 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27Age 50 54 38 58 51 55 60 33 42 60 49 56 49 44 59 57 69 52 60 58 63 66 64 56 45 60 41Differentiation Moderate Poor Well Poor Poor Moderate Poor Poor Poor Poor Moderate Poor Poor Well Poor Moderate Poor Poor Poor Moderate Poor Poor Moderate Poor Poor Poor Poor ModerateFIGO stage IIIb IIIc IIc IIIc IIIc IIIb IIIc IIIc IVa IIIc IIb IIIc IIIc IIIc IIIb IVa IIIc IIIc IIIa IIIc IIIc IIIb IIIc IIIb IIIc IIIc IIIc IIIcRegimen after primary GW0918 surgery Paclitaxel/carboplatin Paclitaxel/carboplatin Paclitaxel/carboplatin Paclitaxel/cisplatin Doxepaclitaxel/carboplatin Paclitaxel/cisplatin Doxepaclitaxel/carboplatin Doxepaclitaxel/carboplatin Paclitaxel/cisplatin Paclitaxel/carboplatin; Doxepaclitaxel/ carboplatin** Paclitaxel/carboplatin Paclitaxel/carboplatin; Paclitaxel/cisplatin*** Paclitaxel/carboplatin Doxepaclitaxel/cisplatin Paclitaxel/carboplatin Paclitaxel/carboplatin; Doxepaclitaxel/ carboplatin** Paclitaxel/cisplatin Paclitaxel/carboplatin Doxepaclitaxel/carboplatin Paclitaxel/carboplatin Paclitaxel/carboplatin Doxepaclitaxel/carboplatin; Doxepaclitaxel/ cisplatin*** Paclitaxel/cisplatin Doxepaclitaxel/carboplatin Paclitaxel/carboplatin; Doxepaclitaxel/ carboplatin** Paclitaxel/carboplatin Paclitaxel/cisplatin Doxepaclitaxel/carboplatinEvaluation* Sensitive Sensitive Sensitive Sensitive Sensitive Sensitive Sensitive Sensitive Sensitive Sensitive Sensitive Sensitive Sensitive Sensitive Sensitive Sensitive Sensitive Sensitive Sensitive Resistance Resistance Resistance Resistance Resistance Resistance Resistance Resistance ResistanceDIGE (+.And 8 down-regulated proteins, in ascites of chemoresistant tumors compared with chemosensitive tumors were successfully identified. The peptide count of the identified proteins varied from 4 to 33. Fold changes of levels of the 11 identified proteins in the two groups along with the detailed Mascot search results are given in Table 2. Several proteins were identified in multiple spots. For example, spots 1421, 1593, and 1598 were each identified as the transthyretin protein, which is a transport and acute phase protein, or its variants. Similarly, spots 1614 and 1626 were identified as haptoglobin, while spots 1536 and 1543 wereELISA ValidationAscites samples 12926553 (5 mL) were centrifuged at 2,000 rpm for 15 min at 4uC to separate the fluid from cellular components. The suspension was briefly 
sonicated, and the debris was centrifuged at 14,000 rpm for 10 min at 4uC. The supernatant was resuspended and stored at 280uC. ELISA assay kits for each of the analytes selected for further analysis were purchased from Abcam. These analytes were as follows: apoliprotein A-IV (Apo-AIV), ceruloplasmin, transthyretin and haptoglobin. Assays were performed following the instructions of the kit. Briefly, the color change due to the enzyme-substrate reaction of each well in the microtiter plate was measured spectrophotometrically at a wavelength of 450 nm. The concentration of each tested protein in the sample was then determined by comparing the optical density (OD) to that of the standard curve. Student’s t-test was conducted to compare differences between serum protein values. The SPSS 16.0 software package (SPSS, Chicago, IL, USA) was used to conduct the statistical analyses, and a two-tailed P value of less than 0.05 was considered statistically significant.Biomarkers for Chemoresistant Ovarian CancerTable 1. Clinical characteristics of study subjects.No 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27Age 50 54 38 58 51 55 60 33 42 60 49 56 49 44 59 57 69 52 60 58 63 66 64 56 45 60 41Differentiation Moderate Poor Well Poor Poor Moderate Poor Poor Poor Poor Moderate Poor Poor Well Poor Moderate Poor Poor Poor Moderate Poor Poor Moderate Poor Poor Poor Poor ModerateFIGO stage IIIb IIIc IIc IIIc IIIc IIIb IIIc IIIc IVa IIIc IIb IIIc IIIc IIIc IIIb IVa IIIc IIIc IIIa IIIc IIIc IIIb IIIc IIIb IIIc IIIc IIIc IIIcRegimen after primary surgery Paclitaxel/carboplatin Paclitaxel/carboplatin Paclitaxel/carboplatin Paclitaxel/cisplatin Doxepaclitaxel/carboplatin Paclitaxel/cisplatin Doxepaclitaxel/carboplatin Doxepaclitaxel/carboplatin Paclitaxel/cisplatin Paclitaxel/carboplatin; Doxepaclitaxel/ carboplatin** Paclitaxel/carboplatin Paclitaxel/carboplatin; Paclitaxel/cisplatin*** Paclitaxel/carboplatin Doxepaclitaxel/cisplatin Paclitaxel/carboplatin Paclitaxel/carboplatin; Doxepaclitaxel/ carboplatin** Paclitaxel/cisplatin Paclitaxel/carboplatin Doxepaclitaxel/carboplatin Paclitaxel/carboplatin Paclitaxel/carboplatin Doxepaclitaxel/carboplatin; Doxepaclitaxel/ cisplatin*** Paclitaxel/cisplatin Doxepaclitaxel/carboplatin Paclitaxel/carboplatin; Doxepaclitaxel/ carboplatin** Paclitaxel/carboplatin Paclitaxel/cisplatin Doxepaclitaxel/carboplatinEvaluation* Sensitive Sensitive Sensitive Sensitive Sensitive Sensitive Sensitive Sensitive Sensitive Sensitive Sensitive Sensitive Sensitive Sensitive Sensitive Sensitive Sensitive Sensitive Sensitive Resistance Resistance Resistance Resistance Resistance Resistance Resistance Resistance ResistanceDIGE (+.
